Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

• Status: Completed
• Trial end date: 1969-12-31

Summary

Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis

• Phase: Phase 3

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Indomethacin; Meloxicam